II. Indications
- Prostate Cancer (Hormone-refractory, metastatic)
III. Contraindications
- Impaired Hepatic Function
- QTc Prolongation
IV. Mechanism
- See Mitotic Inhibitor Chemotherapy
- Cabazitaxel is a taxane Antimitotic Agent with antineoplastic agent
- Semi-synthetic derivative of the natural taxoid, 10-deacetylbaccatin 3
- Cabazitaxel binds tubulin
- Inhibits microtubule depolymerization
- Inhibits cell division, arresting the cell cycle in G2/M phase
- Inhibits tumor cell proliferation
- Cabazitaxel is unique among Taxanes
- Binds poorly to the P-Glycoprotein efflux pump (potential activity against mutidrug resistant tumors)
- Penetrates the blood brain barrier
V. Medications
- Cabazitaxel Intravenous Solution: 60 mg in 1.5 ml vial (dilute in 5.7 ml supplied diluent)
VI. Dosing
- See other references for disease specific dosing protocols
-
Prostate Cancer (Hormone-refractory, metastatic)
- Cabazitaxel 25 mg/m2 IV every 3 weeks AND
- Prednisone 10 mg orally daily for entire treatment course
- Premedicate each dose (30 minutes prior)
- Dexamethasone 8 mg or equivalent AND
- Antihistamine and H2 Blocker
VII. Adverse Effects
- Myelosuppression (Bone Marrow Suppression)
- Neutropenia (severe)
- Hypersensitivity Reaction (severe)
- Diarrhea (severe)
- Pulmonary effects
VIII. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters)
- Use reliable Contraception
- Monitoring